MARKET

PTGX

PTGX

Protagonist Ther
NASDAQ
18.56
+0.35
+1.92%
After Hours: 18.54 -0.02 -0.11% 19:59 12/01 EST
OPEN
18.12
PREV CLOSE
18.21
HIGH
18.75
LOW
17.70
VOLUME
454.29K
TURNOVER
0
52 WEEK HIGH
30.10
52 WEEK LOW
7.45
MARKET CAP
1.07B
P/E (TTM)
-7.0983
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at PTGX last week (1120-1124)?
Weekly Report · 6d ago
Weekly Report: what happened at PTGX last week (1113-1117)?
Weekly Report · 11/20 11:24
Protagonist Therapeutics Earns ‘Buy’ Rating on Strength of Drug Pipeline and Potential Royalties
TipRanks · 11/15 11:28
Weekly Report: what happened at PTGX last week (1106-1110)?
Weekly Report · 11/13 11:17
Does Protagonist Therapeutics (PTGX) Have the Potential to Rally 141.08% as Wall Street Analysts Expect?
NASDAQ · 11/09 14:55
Weekly Report: what happened at PTGX last week (1030-1103)?
Weekly Report · 11/06 11:22
The Latest Analyst Ratings for Protagonist Therapeutics
Benzinga · 11/03 20:00
JMP Securities Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $37
Benzinga · 11/03 19:49
More
About PTGX
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. Its clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the treatment of erythrocytosis, iron overload and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned, investigational, orally delivered, gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).

Webull offers Protagonist Therapeutics Inc stock information, including NASDAQ: PTGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTGX stock methods without spending real money on the virtual paper trading platform.